Medizone Home
×

Epirus expands biosimilar pipeline and capabilities

Epirus Biopharmaceuticals, Inc., announced an agreement for the acquisition of Bioceros Holding B.V., enabling Epirus to expand its biosimilar pipeline and vertically integrate product development ...

FDA approves first biosimilar Zarxio (filgrastim-sndz) from Sandoz

Sandoz, a Novartis company, announced that the US Food and Drug Administration (FDA) approved Zarxio (filgrastim-sndz) for all indications included in the reference product’s label. Sandoz is the first ...

Samsung Bioepis submits Enbrel biosimilar to EMA

Samsung Bioepis Co., Ltd., announced that the Marketing Authorization Application (MAA) for its Enbrel (etanercept) biosimilar candidate, SB4 has been validated and accepted for review by European Medicines ...

First Infliximab Biosimilar registered in India

EPIRUS Biopharmaceuticals, Inc. announced that it has received final marketing and manufacturing approvals for its Remicade (infliximab) biosimilar, BOW015, from the Drug Controller General of India (DCGI). ...
Pages:«123